CN Patent

CN114276290B — 一种雷芬那辛无水晶型及其制备方法

Assigned to Hangzhou Hezekunyuan Pharmaceutical Co ltd · Expires 2024-05-28 · 2y expired

What this patent protects

本发明提供一种雷芬那辛无水晶型及其制备方法。所述雷芬那辛无水晶型具有改良的化学稳定性，其X‑射线粉末衍射图谱以2θ±0.20°表示，具有7.05°、9.36°、11.10°、12.90°、17.56°、18.56°、20.00°、21.27°、24.15°的特征峰，TGA分析其结构中不含溶剂，DSC分析其吸热热流的起点温度为91.34℃处（焓为173.0J/g），熔点为106.04℃。

USPTO Abstract

本发明提供一种雷芬那辛无水晶型及其制备方法。所述雷芬那辛无水晶型具有改良的化学稳定性，其X‑射线粉末衍射图谱以2θ±0.20°表示，具有7.05°、9.36°、11.10°、12.90°、17.56°、18.56°、20.00°、21.27°、24.15°的特征峰，TGA分析其结构中不含溶剂，DSC分析其吸热热流的起点温度为91.34℃处（焓为173.0J/g），熔点为106.04℃。

Drugs covered by this patent

Patent Metadata

Patent number
CN114276290B
Jurisdiction
CN
Classification
—
Expires
2024-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Hezekunyuan Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.